评估前列腺癌、黑色素瘤和肺癌监测偏倚的幅度
该研究基于瑞士癌症登记处1989至2021年人群数据,用Joinpoint回归分析年龄标化发病率和死亡率趋势,通过计算两者年均变化绝对归一化差值来估计监测偏倚。前列腺癌在1989-2004、2011-2014和2014-2021年偏倚高,黑色素瘤1989-2003年偏倚高,肺癌全程偏倚低;早期癌偏倚大于晚期癌。
要点
- 前列腺癌监测偏倚在1989-2004年高(绝对归一化差值5%),2004-2011年低(0.3%),2011-2014和2014-2021年高(6%和5%)。
- 黑色素瘤监测偏倚1989-2003年高(5.5%),2003-2021年中等(1.6%);肺癌全程低(0.5%)。
- 分期分析显示早期癌的监测偏倚大于晚期癌。
核心结论
- 可用简便可行的监测偏倚估计方法用于日常监测,但需进一步研究完善估计。
研究设计与样本
- 基于瑞士癌症登记处1989至2021年人群发病率和死亡率数据的回顾性分析。
- 采用Joinpoint回归识别年龄标化发病率趋势分段,并以相同分段分析死亡率趋势。
- 通过计算各时段年龄标化发病率和死亡率年均变化的绝对归一化差值来评估监测偏倚,差值越大偏倚越大。
- 设定三个切点将偏倚分为低、中、高三级,并进行了分期分析。
主要发现
- 前列腺癌监测偏倚:1989-2004年高(绝对归一化差值5%),2004-2011年低(0.3%),2011-2014年高(6%),2014-2021年高(5%)。
- 黑色素瘤监测偏倚:1989-2003年高(绝对归一化差值5.5%),2003-2021年中等(1.6%)。
- 肺癌监测偏倚全程低(绝对归一化差值0.5%)。
- 分期分析中,早期癌的监测偏倚大于晚期癌。
临床怎么用
- 在解读前列腺癌、黑色素瘤和肺癌发病率变化时,应考虑监测偏倚的影响,避免将发病率上升简单归因于真实发病增加。
- 该估计方法可用于日常监测活动,帮助识别偏倚较大的时段和癌种。
局限性
- 需进一步研究完善监测偏倚的估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Changes in cancer incidence can result from changes in screening and diagnostic practices rather than changes in the true occurrence of cancer, leading to surveillance bias. Quantitative approaches to estimate this bias are lacking. OBJECTIVES: To develop an approach to estimate surveillance bias in prostate cancer, melanoma, and lung cancer. METHODS: We used population-based data from Swiss cancer registries on incidence and mortality from 1989 to 2021. Age-standardized incidence was analyzed using Joinpoint regression to identify periods with distinct trends. The same periods were used to segment mortality trends. The magnitude of surveillance bias was assessed for each period by computing the absolute normalized difference between the mean annual changes in age-standardized incidence and mortality rates, since mortality is less affected by screening and diagnostic practices than incidence. Larger differences indicated greater bias. We defined three cut-offs to categorize the bias into low, moderate and high. Analyses were also conducted by cancer stage. RESULTS: Our estimator of surveillance bias for prostate cancer points to a high bias in 1989-2004 (absolute normalized difference= 5%), low in 2004-2011 (absolute normalized difference = 0.3%), and high in 2011-2014 and 2014-2021 (absolute normalized difference = 6% and 5%). For melanoma, the bias was high from 1989 and 2003 and moderate between 2003 and 2021 (absolute normalized difference = 5.5% and 1.6%). For lung cancer, it was low over the entire study period (absolute normalized difference = 0.5%). In stage-specific analyses, surveillance bias was greater for early-stage than advanced-stage cancers. CONCLUSIONS: We estimated surveillance bias using a simple approach that can be used in daily monitoring activities. Further studies are needed to refine these estimates.
引用
- Tancredi S, Cullati S, van der Linden BWA, et al. Assessing the magnitude of surveillance bias in prostate cancer, melanoma and lung cancer. Eur J Cancer. 2026. PMID: 42447515. doi:10.1016/j.ejca.2026.116942
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。